Sumitomo Mitsui Trust Group Inc. Buys 1,294 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 278,241 shares of the biopharmaceutical company’s stock after purchasing an additional 1,294 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.22% of Alnylam Pharmaceuticals worth $76,525,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Alnylam Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock worth $1,792,542,000 after purchasing an additional 50,366 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Alnylam Pharmaceuticals by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after purchasing an additional 201,784 shares in the last quarter. Capital International Investors increased its holdings in Alnylam Pharmaceuticals by 1.8% during the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock worth $545,674,000 after purchasing an additional 64,560 shares in the last quarter. Capital Research Global Investors increased its holdings in Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after purchasing an additional 214,908 shares in the last quarter. Finally, Bellevue Group AG boosted its stake in shares of Alnylam Pharmaceuticals by 3.7% in the 1st quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock worth $137,238,000 after buying an additional 32,966 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. This represents a 16.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 2.5 %

NASDAQ:ALNY opened at $257.91 on Friday. The company has a market cap of $33.27 billion, a P/E ratio of -98.44 and a beta of 0.39. The stock’s fifty day moving average price is $275.18 and its two-hundred day moving average price is $233.68. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the prior year, the company posted $1.15 EPS. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% on a year-over-year basis. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of research analyst reports. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $198.00 to $370.00 in a research note on Friday, August 16th. Barclays boosted their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Needham & Company LLC restated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Finally, Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $294.50.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.